Fate Therapeutics stock fell 7.01 percent on October 16, 2026

Published on 10/17/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts kept the USD 5.90 average target on October 16, 2026. Fate Therapeutics stock stood at USD 1.79 on October 16, 2026, down 7.01 percent on Nasdaq.

Nasdaq trading fell 7.01 percent

Nasdaq trading for Fate Therapeutics fell 7.01 percent on October 16, 2026.
Eight brokerages held a USD 5.90 average target on October 16, 2026.
Fate Therapeutics stock stood at USD 1.79 at 4:00 p.m. ET on October 16, 2026, down 7.01 percent versus the Nasdaq prior close of October 15, 2026.
The next scheduled earnings report is November 12, 2026.

FATE, US31189P1021, Illustration mit AI erstellt.

Fate Therapeutics stock fell 7.01 percent on Nasdaq on October 16, 2026. At 4:00 p.m. ET on October 16, 2026, the stock last stood at USD 1.79, down 7.01 percent versus the Nasdaq prior close of USD 1.93.

Analyst target stays elevated

A report published by Transcript Daily on October 16, 2026 said eight brokerages held a consensus Hold rating and an average 12-month target of USD 5.90. That target stood 229.61 percent above the Nasdaq price of USD 1.79 on October 16, 2026.

Range and volume define the move

The stock's 52-week range was USD 0.95 to USD 3.23 on October 16, 2026. At USD 1.79, it stood 44.58 percent below the high and 88.42 percent above the low. Trading volume reached 1,383,070 shares, compared with an average volume of 1,599,853 shares.

Fate Therapeutics appointed Jamie Harrell as senior vice president for market development and commercial operations on October 12, 2026, according to the company's investor-relations page. The company develops programmed cellular immunotherapies for cancer and immune disorders.

Valuation and reporting date

Fate Therapeutics had a market capitalization of USD 208.6 million on October 16, 2026. Its trailing price-to-earnings ratio was minus 1.70, while its dividend yield was 0.00 percent. The next scheduled earnings report is November 12, 2026, according to Earnings Today.

Comparison with peers

Fate Therapeutics (Nasdaq, USD): minus 7.01 percent, P/E -1.70, market capitalization USD 208.6 million.
Allogene Therapeutics (Nasdaq, USD): minus 2.24 percent, P/E -1.96, market capitalization USD 452.6 million.
CRISPR Therapeutics (Nasdaq, USD): minus 4.41 percent, P/E -10.35, market capitalization USD 4.8 billion.

Next date for investors

The November 12, 2026 reporting date is the next scheduled company event. The October 16 price move leaves the stock below its 52-week high while the average analyst target remains materially higher than the latest Nasdaq quote.